A phase IIa study to examining the efficacy of THX-110 [Dronabinol (synthetic Δ9-tetrahydracannabinol) and Palmitoylethanolamide (PEA)] for Chronic Low Back Pain.
Phase of Trial: Phase II
Latest Information Update: 23 Mar 2018
At a glance
- Drugs Dronabinol/palmitoylethanolamide (Primary)
- Indications Back pain
- Focus Adverse reactions; Therapeutic Use
- 23 Mar 2018 New trial record
- 20 Mar 2018 According to a Therapix Biosciences media release, company expects to commence this study by the second quarter of 2018. Company received the FDA clearance for IND of THX-110 in the treatment of Chronic Low Back Pain.